000 01656nam a2200433 i 4500
001 ocn951215147
003 BD
005 20161116131536.0
008 160606s2016 dcu l f000 0 eng c
040 _aPUCPR
_beng
_erda
_cGPO
041 _aspa
042 _apcc
043 _an-us---
049 _aBDCG
050 _aKF 50
_b.U56
074 _a0575
086 0 _aAE 2.110:114-146
088 _aPublic Law 114-146
099 _aAE 2.110:114-146
110 1 _aUnited States,
_eenacting jurisdiction.
240 1 0 _aAdding Zika Virus to the FDA Priority Review Voucher Program Act
245 1 3 _aAn Act to Expand the Tropical Disease Product Priority Review Voucher Program to Encourage Treatments for Zika Virus.
264 1 _a[Washington, D.C.] :
_b[U.S. Government Publishing Office],
_c[2016]
300 _a[1] leaf ;
_c24 cm.
336 _atext
_btxt
_2rdacontent
337 _aunmediated
_bn
_2rdamedia
338 _avolume
_bnc
_2rdacarrier
500 _aTitle from caption.
500 _aShipping list no.: 2016-0275-P.
500 _a"Apr. 19, 2016 (S. 2512)."
500 _a"130 Stat. 357."
500 _a"Public Law 114-146."
500 _aCRDP Project record.
610 1 0 _aUnited States.
_bFood and Drug Administration
_xRules and practice.
650 0 _aVirus diseases
_xLaw and legislation
_zUnited States.
655 7 _aStatutes and codes.
_2lcgft
776 0 8 _iOnline version:
_aUnited States.
_sAdding Zika Virus to the FDA Priority Review Voucher Program Act.
_tAct to Expand the Tropical Disease Product Priority Review Voucher Program to Encourage Treatments for Zika Virus
_w(OCoLC)949906329
942 _2lcc
_c15
999 _c253436
_d253436